MINISEMINARS new technology will be asked, including cost-benefit ratios and responsible implementation among general practices.
Program Description: Transoral treatment of larynx and pharynx cancer has been done for over a century. Despite substantial technical innovations such as enhanced imaging, innovative laser technologies, and robotics guidance systems, radiotherapy and/or chemotherapy dominate the treatment strategy at many institutions. In part, this is due to limited familiarity with recent novel endoscopic surgical approaches. Outcomes data on transoral microsurgical management for advanced oropharynx and larynx cancer will be presented to illustrate the efficacy of surgical management of these diseases. Robotics and laser photoangiolysis of laryngeal cancer are two emerging technologies that can enhance endoscopic surgery. These novel and innovative treatment technologies can potentially be combined in the future to expand the indications for endoscopic surgery. This miniseminar will highlight advantages and disadvantages of endoscopic techniques and update the attendees on state-of-the-art procedural innovations.
Educational Objectives: 1) Understand outcomes data on transoral laser microsurgery for advanced oropharyngeal and laryngeal cancer. 2) Understand the emerging role of robotics in endoscopic surgical management of larynx and pharynx cancer.
3) Understand concepts of photoangiolysis in treatment of aerodigestive tract malignancy.
The American Thyroid Association
Guidelines: Do We All Agree? Robert L. Witt, MD (moderator); Arnold Komisar, MD, DDS; Marc D. Coltrera, MD; Ashok R. Shaha, MD; Robert C. Wang, MD; Edmund A. Pribitkin, MD; F. Christopher Holsinger, MD Program Description: The theme of this audience interactive miniseminar is to incorporate what is new and controversial in the management of differentiated thyroid cancer as well as to examine the level that molecular biology is incorporated into the management of thyroid neoplasms. The American Thyroid Guidelines for differentiated thyroid cancer are a widely quoted document. The level of evidence on which these recommendations are made varies extensively leaving considerable room for debate. Some aspects of surgical management such as laryngoscopy, bronchoscopy, and neuro-monitoring are left out of the document. The moderator will provide a brief background power-point presentation on the pertinent ATA guideline as a template. Expert panelists will debate case presentations germane to the given guideline and determine the level of agreement. Audience interactive opinion will be sought. The specific guidelines (where applicable) and case presentations will include: 1) Ultrasound indications for fine needle aspiration and the use of molecular markers from the FNA; 2) Laryngoscopy and neuro-monitoring; 3) Extent of initial surgical therapy for low-risk differentiated thyroid neoplasms and the potential role for molecular markers; 4) Bronchoscopy, preparation for airway management and extent of surgery for high risk patients with extra-thyroidal spread; and 5) Surgery for recurrent differentiated thyroid cancer and the role of molecular targeted therapy. Panelists and the interactive audience will give opinions on the relevance of the ATA guidelines to their thyroid surgical practice.
Educational Objectives: 1) Learn the benefits and limitations of the American Thyroid Association Guidelines. 2) Learn about molecular markers for diagnosis, prognostication, and molecular-targeted therapy. 3) Learn about ultrasound-guided FNA, management of low-and high-risk patients, and recurrence.
Transoral Robotic Surgery: A New Paradigm in the Treatment of Head and Neck Cancer and Reconstructive Surgery
Derrick T. Lin, MD (moderator); Eric M. Genden, MD; J. Scott Magnuson, MD; Jesse Selber, MD Program Description: Transoral robotic head and neck surgery (TORS) has quickly become an accepted alternative approach for treatment of tumors of the upper aerodigestive tract. Specifically, approaches to oropharyngeal tumors have traditionally been through a mandibulotomy or lingual release approach with its associated postoperative morbidity. Because of this potential morbidity and the proven efficacy of chemoradiotherapy, there has been a paradigm shift away from upfront surgical management. With the advent of TORS over the past few years, several reports have documented its safety and improved functional outcomes in the management not only of oropharyngeal tumors but also of hypopharyngeal and laryngeal cancers without sacrificing tumor control or overall survival. As the indications for TORS continue to expand, will there then be an evolving role for robotic-assisted reconstructive surgery? And what are the indications for reconstructions after TORS? The miniseminar will be composed of four parts: First, the moderator will provide a short introduction. The second speaker will review the current literature and their experience with TORS. They will specifically discuss the current indications and functional results without reconstruction. The third speaker will discuss the rationale for robotic free flap reconstruction, its indications and potential improved
